Aernoud Fiolet

302 Chapter 12 When aggregating on level of CYP3A4 isoenzyme metabolism (atorvastatin and simvastatin), patients wo used CYP3A4 isoenzyme substrate statins did not experience higher odds for intolerance due to any side effect as compared to non-CYP3A4 isoenzyme substrate statins. However, significant lower odds for intolerance due to myalgia were observed in patients using CYP3A4 isoenzyme substrates as compared to non-CYP3A4 isoenzyme substrate statins (1.0% versus 2.9% respectively, odds ratio 0.34; 92% confidence interval 0.20 to 0.57, p value < 0.001) ( Figure 5b ) Geographic distribution of intolerance Intolerance due to any perceived side effects was reported in all regions that participated. Intolerance varied across regions from 4-5% up to 9-10%. Lowest proportions of intolerance were found in the Northern regions and highest in the upper and middle eastern regions of the country. ( Figure 6 ) Figure 5a: Univariable associations of statins and intolerance. Crude OR Outcome Statin Intolerant (%) OR 95% confidence P Value Forrest plot Any intolerance Atorvastatin 142 (8.1%) 1.04 (0.82 to 1.32) 0.733 Fluvastatin 2 (10.0%) 1.29 (0.2 0 to 4.50) 0.733 Pravastatin 13 (9.0%) 1.16 (0.62 to 2.00) 0.623 Rosuvastatin 81 (9.0%) 1.20 (0.92 to 1.56) 0.174 Simvastatin 61 (6.4%) 0.74 (0.55 to 0.99) 0.046 Gastro-intestinal intolerance Atorvastatin 88 (5.0%) 1.07 (0.79 to 1.44) 0.669 Fluvastatin 1 (5.0%) 1.03 (0.06 to 5.01) 0.977 Pravastatin 8 (5.6%) 1.16 (0.51 to 2.25) 0.692 Rosuvastatin 46 (5.1%) 1.07 (0.76 to 1.50) 0.681 Simvastatin 40 (4.2%) 0.82 (0.57 to 1.16) 0.283 Myalgia Atorvastatin 21 (1.2%) 0.65 (0.37 to 1.10) 0.114 Fluvastatin 0 (0.0%) NA NA Pravastatin 2 (1.4%) 0.90 (0.15 to 2.91) 0.881 Rosuvastatin 29 (3.2%) 3.26 (1.93 to 5.50) <0.001 Simvastatin 6 (0.6%) 0.34 (0.13 to 0.73) 0.012 Figure 5a: Univariable associations of statins and intolerance to low-dose colchicine. Depicted odds are as compared to any other statin. Abbrevations: NA, not apllicable; OR, odds ratio Figure 5a: Univariable associations of statins and intolerance to low-dose colchicine. Depicted odds are as compared to any other statin. Abbrevations: NA, not applicable; OR, odds ratios